LYTIR

Insider · SEC Form 4 · President and Chief Executive Officer

David Kirn

Filed with the SEC as Kirn David; the order above is the one the filer's own signature uses.

In the 12 months to Nov 8, 2026, on the open market: sold $5.0M of FDMT. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $5.0M in total.Jun: Insider sales $1.2MJul: Insider sales $737KAug: Insider sales $1.5MSep: Insider sales $811KOct: Insider sales $754KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $5.0M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. FDMTSold: 4D Molecular Therapeutics, Inc. Oct 5, 2026 58,333 shares filed Oct 7, 2026 2 transactions 10b5-1 plan filing $754K
  2. FDMTSold: 4D Molecular Therapeutics, Inc. Sep 14, 2026 58,333 shares filed Sep 16, 2026 767,486 shares held directly after, as filed 10b5-1 plan filing $811K
  3. FDMTSold: 4D Molecular Therapeutics, Inc. Aug 19, 2026 69,076 shares filed Aug 21, 2026 2 transactions 10b5-1 plan filing $1.1M
  4. FDMTSold: 4D Molecular Therapeutics, Inc. Aug 4, 2026 26,842 shares filed Aug 5, 2026 844,895 shares held directly after, as filed 10b5-1 plan filing $275K
  5. FDMTSold: 4D Molecular Therapeutics, Inc. Aug 3, 2026 12,415 shares filed Aug 4, 2026 871,737 shares held directly after, as filed 10b5-1 plan filing $125K
  6. FDMTSold: 4D Molecular Therapeutics, Inc. Jul 10, 2026 15,725 shares filed Jul 14, 2026 2 transactions 10b5-1 plan filing $189K
  7. FDMTSold: 4D Molecular Therapeutics, Inc. Jul 9, 2026 42,608 shares filed Jul 14, 2026 899,877 shares held directly after, as filed 10b5-1 plan filing $548K
  8. FDMTSold: 4D Molecular Therapeutics, Inc. Jun 22, 2026 114,746 shares filed Jun 23, 2026 942,485 shares held directly after, as filed 10b5-1 plan filing $1.2M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • FDMT: option exercise or conversion (code M), 1 entry, Aug 19, 2026
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.